Somewhere between early discovery and tech transfer, a decision gets made that most non-scientists never see coming: which crystal form of the API will carry the program forward. Get it wrong, and the bill arrives much later — as a failed stability batch, a blocked patent claim, or a manufacturing process that won’t scale.
The Decision Hiding Inside a Technical Milestone
Solid form selection is usually framed as a lab deliverable: a report, a recommended polymorph, a line item in the CMC package. For the scientists running the screening, that framing is accurate. For the people accountable for budget, timeline, and regulatory risk, it understates what is actually being decided.
Once a crystal form is selected, it shapes everything downstream — dissolution behavior, manufacturability, stability under storage, and the strength of the patent position. Reopening that decision later, after formulation and process development have built around it, is expensive and slow.
The problem is that this decision often gets made quietly, inside a technical workstream, without the four questions below ever reaching the people who will own the consequences if the form turns out to be wrong.
Question 1: Have We Actually Mapped the Solid-Form Landscape?
Every API has more than one possible crystal form, and sometimes several: polymorphs, hydrates, solvates, salts, co-crystals, or an amorphous state. A narrow screen — a handful of solvents, one or two crystallization conditions — can miss a more stable or more manufacturable form entirely.
This is not an academic concern. A polymorph that appears only under specific humidity or temperature conditions can surface during scale-up, stability testing, or storage at the distribution center, long after the ‘final’ form has been written into the regulatory dossier.
What good looks like is a systematic screen across a meaningful range of conditions, with results documented well enough to show a reviewer — internal or regulatory — that the landscape was genuinely explored, not just sampled.
- Was the screen designed around the compound’s actual physicochemical properties, not a generic template?
- Were thermodynamic stability relationships between forms established, not just forms identified?
- Is there a documented rationale for why the selected form was chosen over the alternatives?
Question 2: Will This Form Survive the Trip From Bench to Shelf?
A crystal form that looks stable in a vial on a bench can behave differently once it meets a jet mill, a tableting press, or a humid warehouse. Mechanical stress, moisture, and temperature cycling during manufacturing and storage are where marginal forms reveal themselves.
The commercial cost of discovering this late is not just a delayed batch. It is reformulated specifications, renegotiated timelines with partners, and in some cases a full return to solid form development after a program has already moved toward clinical supply.
Decision makers should expect to see stress testing that reflects real manufacturing and storage conditions — not just standard ICH stability chambers, but mechanical and humidity stress relevant to how the API will actually be handled.
Question 3: Can We Defend This Form — Scientifically and Legally?
Solid form choices sit at the intersection of chemistry and intellectual property. A novel, well-characterized form can extend or strengthen a patent position. A poorly documented one can leave a program exposed to challenge, or worse, unable to defend exclusivity at all.
This question matters as much to business development and licensing teams as it does to scientists. A buyer, licensor, or investor evaluating a program will ask whether the solid form is adequately characterized and whether the IP position around it is sound.
The practical test is simple: if a regulatory agency or a patent examiner challenged the selected form tomorrow, would the data package hold up, or would it raise more questions than it answers?
Question 4: Does Our Partner Match the Compound’s Risk Profile?
Not every solid-form question can be answered safely, or legally, in a generalist lab. High-potency compounds and controlled substances carry handling, containment, and authorization requirements that go beyond standard analytical work.
A mismatch here costs more than money. Projects get delayed waiting for a partner to secure the right authorization, or worse, get rerouted mid-program when a lab discovers it cannot handle the containment level the compound requires.
For HPAPIs up to OEB5 and for controlled substances, the practical question for procurement and BD leaders is whether the chosen partner already holds the relevant authorizations and containment infrastructure, or whether that capability still needs to be built, licensed, or subcontracted.
What Good Looks Like: A Decision Framework
Across these four questions, a pattern emerges. Good solid-form decisions are not faster because they skip steps — they are faster because the right steps are done once, early, and documented well enough that they do not need to be revisited under pressure later.
For teams evaluating whether a solid-form package is ready to lock, the following markers are a useful checklist before signing off.
- A documented, condition-based screen covering a meaningful range of solvents, temperatures, and crystallization methods.
- Stress testing under realistic mechanical, humidity, and temperature conditions, not only standard storage stability.
- A clear, defensible rationale — in writing — for why the selected form was chosen over viable alternatives.
- Characterization data robust enough to support both the regulatory dossier and the IP position.
- A partner with the containment infrastructure and regulatory authorizations that match the compound’s actual risk category, confirmed before work begins, not after.
None of this requires turning a procurement or project management team into solid-state chemists. It requires knowing which four questions to ask, and insisting on documented answers before a crystal form is treated as final. If your program is approaching that decision point, PCL Research & Manufacturing is glad to talk through where your current solid-form package stands — no commitment required, just a technical conversation between people who have seen where these decisions tend to go wrong.
